BioCryst Pharmaceuticals Statistics

Total Valuation

BCRX has a market cap or net worth of $1.60 billion. The enterprise value is $2.07 billion.

Market Cap	1.60B
Enterprise Value	2.07B

Important Dates

The last earnings date was Monday, November 3, 2025, before market open.

Earnings Date	Nov 3, 2025
Ex-Dividend Date	n/a

Share Statistics

BCRX has 210.54 million shares outstanding. The number of shares has increased by 1.84% in one year.

Current Share Class	210.54M
Shares Outstanding	210.54M
Shares Change (YoY)	+1.84%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	1.03%
Owned by Institutions (%)	87.38%
Float	180.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	27.53
PS Ratio	2.64
Forward PS	2.42
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	33.39
P/OCF Ratio	31.84
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 25.72, with an EV/FCF ratio of 43.22.

EV / Earnings	n/a
EV / Sales	3.45
EV / EBITDA	25.72
EV / EBIT	26.74
EV / FCF	43.22

Financial Position

The company has a current ratio of 1.87

Current Ratio	1.87
Quick Ratio	1.60
Debt / Equity	n/a
Debt / EBITDA	8.27
Debt / FCF	14.27
Interest Coverage	0.87

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	10.31%
Return on Invested Capital (ROIC)	14.46%
Return on Capital Employed (ROCE)	30.20%
Revenue Per Employee	$1.03M
Profits Per Employee	-$15,136
Employee Count	580
Asset Turnover	1.28
Inventory Turnover	29.60

Taxes

In the past 12 months, BCRX has paid $2.16 million in taxes.

Income Tax	2.16M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.55% in the last 52 weeks. The beta is 0.91, so BCRX's price volatility has been similar to the market average.

Beta (5Y)	0.91
52-Week Price Change	+3.55%
50-Day Moving Average	7.14
200-Day Moving Average	8.30
Relative Strength Index (RSI)	59.48
Average Volume (20 Days)	4,051,819

Short Selling Information

The latest short interest is 36.46 million, so 17.32% of the outstanding shares have been sold short.

Short Interest	36.46M
Short Previous Month	32.47M
Short % of Shares Out	17.32%
Short % of Float	20.15%
Short Ratio (days to cover)	5.01

Income Statement

In the last 12 months, BCRX had revenue of $599.82 million and -$8.78 million in losses. Loss per share was -$0.05.

Revenue	599.82M
Gross Profit	410.45M
Operating Income	77.36M
Pretax Income	-6.62M
Net Income	-8.78M
EBITDA	80.43M
EBIT	77.36M
Loss Per Share	-$0.05

Full Income Statement

Balance Sheet

The company has $212.87 million in cash and $683.11 million in debt, giving a net cash position of -$470.24 million or -$2.23 per share.

Cash & Cash Equivalents	212.87M
Total Debt	683.11M
Net Cash	-470.24M
Net Cash Per Share	-$2.23
Equity (Book Value)	-387.89M
Book Value Per Share	-1.84
Working Capital	165.45M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $50.20 million and capital expenditures -$2.34 million, giving a free cash flow of $47.86 million.

Operating Cash Flow	50.20M
Capital Expenditures	-2.34M
Free Cash Flow	47.86M
FCF Per Share	$0.23

Full Cash Flow Statement

Margins

Gross margin is 68.43%, with operating and profit margins of 12.90% and -1.46%.

Gross Margin	68.43%
Operating Margin	12.90%
Pretax Margin	-1.10%
Profit Margin	-1.46%
EBITDA Margin	13.41%
EBIT Margin	12.90%
FCF Margin	7.98%

Dividends & Yields

BCRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.84%
Shareholder Yield	-1.84%
Earnings Yield	-0.55%
FCF Yield	2.99%

Dividend Details

Analyst Forecast

The average price target for BCRX is $19.00, which is 150.33% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$19.00
Price Target Difference	150.33%
Analyst Consensus	Strong Buy
Analyst Count	11
Revenue Growth Forecast (5Y)	19.54%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BCRX has an Altman Z-Score of -1.89 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.89
Piotroski F-Score	6